Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Cord Blood Takes Hit on Secondary Offering

publication date: Nov 8, 2010
On Friday, China Cord Blood Corporation priced a secondary issue of 8,050,000 ordinary shares at $4.50 per share, a steep 20% discount to the previous close of $5.66. Shareholders didn’t like the size of the discount and reacted by selling off their holdings of the company. The shares plunged $1.69 lower to $3.97, a 30% loss on very heavy volume. More details....

Stock Symbol: (NYSE: CO)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital